Brooklyn Stock Performance

BTX
 Stock
  

USD 0.64  0.05  8.47%   

The firm shows a Beta (market volatility) of 1.8904, which signifies a somewhat significant risk relative to the market. Let's try to break down what Brooklyn's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Brooklyn Immunotherapeuti will likely underperform. Even though it is essential to pay attention to Brooklyn Immunotherapeuti historical returns, it is always good to be careful when utilizing equity current trending patterns. Our philosophy towards foreseeing any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Brooklyn Immunotherapeutics exposes twenty-seven different technical indicators, which can help you to evaluate its performance. Brooklyn Immunotherapeuti has an expected return of -1.52%. Please be advised to confirm Brooklyn Immunotherapeuti maximum drawdown, as well as the relationship between the skewness and day typical price to decide if Brooklyn Immunotherapeuti performance from the past will be repeated at some point in the near future.
  
Refresh
Brooklyn Performance
0 of 100
Over the last 90 days Brooklyn Immunotherapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in August 2022. The current disturbance may also be a sign of long term up-swing for the company investors. ...more

Structure and Payout Changes

Last Split Factor
1:2
Last Split Date
2021-03-26

Brooklyn Price Channel

Quick Ratio4.80
Fifty Two Week Low0.4600
Target High Price5.00
Fifty Two Week High16.3300
Target Low Price4.00

Brooklyn Immunotherapeuti Relative Risk vs. Return Landscape

If you would invest  178.00  in Brooklyn Immunotherapeutics on April 7, 2022 and sell it today you would lose (116.00)  from holding Brooklyn Immunotherapeutics or give up 65.17% of portfolio value over 90 days. Brooklyn Immunotherapeutics is generating negative expected returns assuming volatility of 6.2679% on return distribution over 90 days investment horizon. In other words, 54% of stocks are less volatile than Brooklyn, and above 99% of all equities are expected to generate higher returns over the next 90 days.
 Daily Expected Return (%) 
      Risk (%) 
Considering the 90-day investment horizon Brooklyn Immunotherapeuti is expected to under-perform the market. In addition to that, the company is 4.29 times more volatile than its market benchmark. It trades about -0.24 of its total potential returns per unit of risk. The DOW is currently generating roughly -0.11 per unit of volatility.

Brooklyn Immunotherapeuti Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Brooklyn Immunotherapeuti's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Brooklyn Immunotherapeutics, and traders can use it to determine the average amount a Brooklyn Immunotherapeuti's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = -0.2422

Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small Returns
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
Negative ReturnsBTX
Estimated Market Risk
 6.27
  actual daily
 
 54 %
of total potential
 
5454
Expected Return
 -1.52
  actual daily
 
 0 %
of total potential
 
00
Risk-Adjusted Return
 -0.24
  actual daily
 
 0 %
of total potential
 
00
Based on monthly moving average Brooklyn Immunotherapeuti is performing at about 0% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Brooklyn Immunotherapeuti by adding it to a well-diversified portfolio.

About Brooklyn Immunotherapeuti Performance

To evaluate Brooklyn Immunotherapeuti Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Brooklyn Immunotherapeuti generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Brooklyn Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Brooklyn Immunotherapeuti stock market performance in a much more refined way. At Macroaxis, we take it even further. The Macroaxis performance score is an integer between 0 and 100 that represents Brooklyn's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Effect of Exchange Rate Changes on Cash48.3 K52.1 K
Return on Investment(22.48) (24.25) 
Return on Average Assets(3.11) (3.20) 
Return on Average Equity(9.73) (9.98) 
Return on Invested Capital(11.73) (12.04) 
Return on Sales(0.10) (0.11) 
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.

Things to note about Brooklyn Immunotherapeuti

Checking the ongoing alerts about Brooklyn Immunotherapeuti for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Brooklyn Immunotherapeuti help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Brooklyn Immunotherapeuti Alerts

Equity Alerts and Improvement Suggestions

Brooklyn Immunotherapeuti generated a negative expected return over the last 90 days
Brooklyn Immunotherapeuti has high historical volatility and very poor performance
Brooklyn Immunotherapeuti has some characteristics of a very speculative penny stock
Brooklyn Immunotherapeutics was previously known as BROOKLYN IMMUNOTHERAPEUTICS INC and was traded on NYSEMKT Exchange under the symbol NTN.
The company reported the last year's revenue of 3.45 M. Reported Net Loss for the year was (122.32 M) with profit before taxes, overhead, and interest of 4.69 M.
Brooklyn Immunotherapeutics has about 16.98 M in cash with (23.49 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.3.
Brooklyn Immunotherapeuti has a poor financial position based on the latest SEC disclosures
Roughly 42.0% of the company shares are held by company insiders
Latest headline from MacroaxisInsider: Exercise or conversion by Damour Kevin of 17573 shares of Brooklyn Immunotherapeuti subject to Rule 16b-3
Continue to Trending Equities. Note that the Brooklyn Immunotherapeuti information on this page should be used as a complementary analysis to other Brooklyn Immunotherapeuti's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Brooklyn Stock analysis

When running Brooklyn Immunotherapeuti price analysis, check to measure Brooklyn Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brooklyn Immunotherapeuti is operating at the current time. Most of Brooklyn Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of Brooklyn Immunotherapeuti's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brooklyn Immunotherapeuti's price. Additionally, you may evaluate how the addition of Brooklyn Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Is Brooklyn Immunotherapeuti's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brooklyn Immunotherapeuti. If investors know Brooklyn will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brooklyn Immunotherapeuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
30.9 M
Return On Assets
-0.65
Return On Equity
-17.56
The market value of Brooklyn Immunotherapeuti is measured differently than its book value, which is the value of Brooklyn that is recorded on the company's balance sheet. Investors also form their own opinion of Brooklyn Immunotherapeuti's value that differs from its market value or its book value, called intrinsic value, which is Brooklyn Immunotherapeuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brooklyn Immunotherapeuti's market value can be influenced by many factors that don't directly affect Brooklyn Immunotherapeuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brooklyn Immunotherapeuti's value and its price as these two are different measures arrived at by different means. Investors typically determine Brooklyn Immunotherapeuti value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brooklyn Immunotherapeuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.